Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The transcription factor BCL11A has recently been reported to be a driving force in triple-negative breast cancer (TNBC), contributing to the maintenance of a chemoresistant breast cancer stem cell (BCSC) population. Although BCL11A was shown to suppress γ-globin and p21 and to induce MDM2 expression in the hematopoietic system, its downstream targets in TNBC are still unclear. For its role in transcriptional repression, BCL11A was found to interact with several corepressor complexes; however, the mechanisms underlying these interactions remain unknown. Here, we reveal that BCL11A interacts with histone methyltransferase (PRC2) and histone deacetylase (NuRD and SIN3A) complexes through their common subunit, RBBP4/7. In fluorescence polarization assays, we show that BCL11A competes with histone H3 for binding to the negatively charged top face of RBBP4. To define that interaction, we solved the crystal structure of RBBP4 in complex with an N-terminal peptide of BCL11A (residues 2-16, BCL11A(2-16)). The crystal structure identifies novel interactions between BCL11A and the side of the β-propeller of RBBP4 that are not seen with histone H3. We next show that BCL11A(2-16) pulls down RBBP4, RBBP7, and other components of PRC2, NuRD, and SIN3A from the cell lysate of the TNBC cell line SUM149. Furthermore, we demonstrate the therapeutic potential of targeting the RBBP4-BCL11A binding by showing that a BCL11A peptide can decrease aldehyde dehydrogenase-positive BCSCs and mammosphere formation capacity in SUM149. Together, our findings have uncovered a previously unidentified mechanism that BCL11A may use to recruit epigenetic complexes to regulate transcription and promote tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Epigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143
Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
Charafe-Jauffret, E., Ginestier, C., Iovino, F., Tarpin, C., Diebel, M., Esterni, B., Houvenaeghel, G., Extra, J.-M., Bertucci, F., Jacquemier, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1630 · Cited by 732
Poised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A
Xu, J., Bauer, D. E., Kerenyi, M. A., Vo, T. D., Hou, S., Hsu, Y.-J., Yao, H., Trowbridge, J. J., Mandel, G., & Orkin, S. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303976110 · Cited by 233 · cited 3×
“Indeed, we recognized B-cell lymphoma/leukemia 11A (BCL11A), a zinc-finger transcription factor that is necessary for hematopoiesis and regulates developmental globin switching (23), as a potential interacting partner of RBBP4/7.”
BackgroundLauberth, S. M., & Rauchman, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513461200 · Cited by 140 · cited 1×
“Consistent with our structure in which Arg-3 is disordered, this residue is not an important mediator for interactions between RBBP4 and other transcription factors (21, 22).”
BackgroundKloet, S. L., Baymaz, H. I., Makowski, M., Groenewold, V., Jansen, P. W. T. C., Berendsen, M., Niazi, H., Kops, G. J., & Vermeulen, M. (2015) · The FEBS Journal · doi:10.1111/febs.12972 · Cited by 107
Gao, C., Dimitrov, T., Yong, K. J., Tatetsu, H., Jeong, H.-W., Luo, H. R., Bradner, J. E., Tenen, D. G., & Chai, L. (2013) · Blood · doi:10.1182/blood-2012-04-424275 · Cited by 65 · cited 1×
“This result is consistent with other similar studies using SALL4 as the bait (26).”
ResultConnarn, J. N., Assimon, V. A., Reed, R. A., Tse, E., Southworth, D. R., Zuiderweg, E. R. P., Gestwicki, J. E., & Sun, D. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519421 · Cited by 48 · cited 1×
“Peptides were synthesized as described previously (37).”
Self-citation
Cited by
Yu, J.-R., Lee, C.-H., Oksuz, O., Stafford, J. M., & Reinberg, D. (2019) · Genes & Development · doi:10.1101/gad.325050.119 · Cited by 257
Emerging genetic therapy for sickle cell disease
Orkin, S. H., & Bauer, D. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041817-125507 · Cited by 119
Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide
Liu, B. H., Jobichen, C., Chia, C. S. B., Chan, T. H. M., Tang, J. P., Chung, T. X. Y., Li, J., Poulsen, A., Hung, A. W., Koh-Stenta, X., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801253115 · Cited by 67
Zhang, T., Wang, Y.-F., Montoya, A., Patrascan, I., Nebioglu, N., Pallikonda, H. A., Georgieva, R., King, J. W. D., Kramer, H. B., Shliaha, P. V., et al. (2025) · Blood · doi:10.1182/blood.2024024787 · Cited by 14
Metadata
- Authors
- Moody, R. R., Lo, M.-C., Meagher, J. L., Lin, C.-C., Stevers, N. O., Tinsley, S. L., Jung, I., Matvekas, A., Stuckey, J. A., & Sun, D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 293
- Issue
- 6
- Pages
- 2125-2136
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2778104188
- Cited by
- 68
- References
- 10
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.